Of the six patients who have completed the study to date, three patients (colorectal, melanoma and lung cancer) experienced tumour regression in the target tumour, as well as stable disease
in non-treated tumours.
It is also encouraging to see Phase I patients with poor prognosis experience long periods of stable disease
after single therapy with CYC202.
NASDAQ: ZIOP), announced findings from a phase I study of ZIO-101, a proprietary organic arsenic, showed that 43 percent of relapsing, progressing multiple myeloma patients experienced stable disease
and that the drug was well tolerated in all 14 patients in the study group.
In addition, previous Phase II studies, conducted in Europe on 125 patients with advanced MDS, demonstrated positive results: Of 121 evaluable patients, a response rate of 49 percent was observed, and an additional sixteen percent of the patients experienced stable disease
Among these 23 patients, two have experienced confirmed partial responses and seven others had stable disease
for at least six months, with the most severe adverse events (Grade 3) reported being anemia, increased blood amylase, headache, hypertension, proteinuria and vomiting.